Last updated on October 2018

A Double-Blind, Randomized, Placebo Controlled Study of CM_AT for the Treatment of Autism in Children 3-8 Years Old. (The Blüm Study)


Brief description of study

A Double-Blind, Randomized, Placebo Controlled Study of CM_AT for the Treatment of Autism in Children 3-8 Years Old. (The Blüm Study)

Detailed Study Description

Autism is clearly a significant cause of disability in the pediatric population. Many children with Autism exhibit impaired protein digestion which may or may not manifest in self-restricted diets. The inability to digest protein affects the availability of essential amino acids in the body. CM-AT is designed to enhance protein digestion thereby potentially restoring the pool of essential amino acids. Essential amino acids play a critical role in the expression of several genes important to neurological function and serve as precursors to key neurotransmitters such as serotonin and dopamine.

CM-AT is a proprietary enzyme that is designed as a granulated powder to be taken three times daily.

Watch this video to learn more about the Blüm Study, the clinical trial of CM-AT, an investigational new drug, for the treatment of Autism in children 3-8 years of age.

The Blüm Study

Clinical Study Identifier: TX142059

Contact Investigators or Research Sites near you

Start Over
Sorry. There are no research Sites conducting this study in the radius provided. ( View all Sites )

Recruitment Status: Closed


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.